Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued vs Discontinued Immunosuppression After Late Renal Graft Failure
2023-506879-98-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Nov 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus and cyclosporine in end-stage kidney disease (ESKD), Kidney allograft failure and Allosensitization (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: HLA sensitization at 2 years (cPRA %). Planned start Nov 2023; status: authorised.
02
Drugs
tacrolimuscyclosporine
03
Conditions
end-stage kidney disease (ESKD)Kidney allograft failureAllosensitization
Beyond the preview
Go deeper on 2023-506879-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506879-98-00.